Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains - Pfizer ( NYSE:PFE )
A Phase 3 study funded by Pfizer Inc. ( NYSE:PFE ) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way ...
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
The pharmaceutical giant's post-Keytruda plans continue to take shape.
Is AtriCure ( ATRC ) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Shares in the biotech company have surged on news of a big pharma takeover.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
This Fund Sold $49 Million of Cidara Stock - Then Merck Announced a $9.2 Billion Takeover
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared-but seemingly missed out on a massive premium by mere weeks.
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Cidara Therapeutics ( NASDAQ:CDTX )
As of Nov. 17, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher - Amaze Holdings ( AMEX:AMZE ) , Cidara Therapeutics ( NASDAQ:CDTX )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Friday. The Dow traded down 0.44% to 47,249.55 while the NASDAQ rose 0.59% to 23,004.91. The S&P 500 also rose, gaining, 0.27% to 6,755.73. Utilities shares rose by 0.1% on Friday.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. ( Nasdaq - CDTX ) , Mersana Therapeutics, Inc. ( Nasdaq - MRSN ) , TreeHouse Foods Inc. ( NYSE - THS ) , Gulf Island Inc. ( Nasdaq - GIFI )
BALA CYNWYD, Pa., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat ( NASDAQ:BYND ) , Avadel Pharmaceuticals ( NASDAQ:AVDL )
U.S. stocks were lower, with the Dow Jones index falling more than 500 points on Friday. Shares of Legence Corp ( NASDAQ:LGN ) rose sharply during Friday's session after delivering mixed third-quarter results in its first earnings report since going public.
Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings - Applied Mat ( NASDAQ:AMAT ) , Amaze Holdings ( AMEX:AMZE )
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 200 points on Friday. Following the market opening Friday, the Dow traded down 1.21% to 46,882.86 while the NASDAQ fell 1.51% to 22,525.90. The S&P 500 also fell, dropping, 1.17% to 6,658.51.
What's Going On With Merck Stock Friday? - Merck & Co ( NYSE:MRK ) , Cidara Therapeutics ( NASDAQ:CDTX )
Merck & Co. Inc. ( NYSE:MRK ) on Friday agreed to acquire Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Binah Capital Group ( NASDAQ:BCG ) , Aspire Biopharma Hldgs ( NASDAQ:ASBP )
Shares of RLX Technology Inc - ADR ( NYSE:RLX ) rose sharply in pre-market trading after the company reported financial results for the third quarter. RLX Technology reported quarterly earnings of 3 cents per share on $158.600 million in sales.
Why Is Cidara Therapeutics ( CDTX ) Stock Trending Overnight? - Cidara Therapeutics ( NASDAQ:CDTX )
Cidara Therapeutics Inc. ( NASDAQ:CDTX ) shares are trending on Friday. Check out the current price of CDTX stock here. CDTX surged 42.23% in after-hours trading on Thursday, closing at $150.75.
Cidara Therapeutics to Participate in November Investor Conferences
SAN DIEGO, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced that company management will participate in the below November ...
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday - Strive ( NASDAQ:ASST ) , American Bitcoin ( NASDAQ:ABTC )
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of Janus Henderson Group plc ( NYSE:JHG ) rose sharply during Monday's session after the company confirmed receiving a non-binding takeover proposal from Trian Fund Management for $46 per share.
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' - Cidara Therapeutics ( NASDAQ:CDTX )
JP Morgan initiated coverage of Cidara Therapeutics Inc. ( NASDAQ:CDTX ) on Friday, citing its lead asset, CD388, for influenza, underscoring the game-changing potential of the product and multi-billion dollar potential in the U.S. alone.
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Why Cidara Therapeutics Stock Crushed It Today
The company earned an important fast-track review designation for a pipeline medication.
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation ...
Cidara Shares Are Trading Higher Friday: What's Going On? - Cidara Therapeutics ( NASDAQ:CDTX )
Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced it has received an award valued up to $339M from the Biomedical ...
Why Cidara Therapeutics Was Such a Healthy Stock Today
The company could have quite a winner on its hands with its most advanced pipeline drug.
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
- Update based on FDA End-of- Phase 2 meeting outcome ...
Cidara Therapeutics ( CDTX ) Upgraded to Buy: Here's What You Should Know
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Black Diamond Therapeutics ( BDTX ) Outpaced Other Medical Stocks This Year?
Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Cidara ( CDTX ) Q2 Cash Surges 163%
Cidara Therapeutics ( NASDAQ:CDTX ) , a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on August 7, 2025. The company reported GAAP earnings per share of $1.65.
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, July 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( C ) ( 4 )
SAN DIEGO, July 01, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of ...
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes.
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of ...
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the closing of its underwritten public offering of ...
FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Allot ( NASDAQ:ALLT ) , AST SpaceMobile ( NASDAQ:ASTS )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of FedEx Corporation FDX fell sharply in today's pre-market trading following soft first-quarter guidance.
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - BlackBerry ( NYSE:BB ) , Allot ( NASDAQ:ALLT )
Shares of BlackBerry Limited BB rose sharply in today's pre-market trading following first-quarter results. BlackBerry reported quarterly earnings of two cents per share, which beat the analyst consensus estimate of zero cents. Quarterly revenue of $121.7 million beat the Street estimate of ...
Cidara Announces Pricing of Upsized Public Offering of Common Stock - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of ...
Cidara Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, June 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced the pricing of an underwritten public offering of ...
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday - Advance Auto Parts ( NYSE:AAP ) , Applied Mat ( NASDAQ:AMAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs lowered Advance Auto Parts, Inc. AAP price target from $48 to $46.
Cidara Announces Proposed Public Offering of Common Stock - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, June 23, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) CDTX, a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its plans to commence an underwritten public offering, subject to ...
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( "Cidara" ) ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today announced its plans to commence an underwritten public offering, ...
Crude Oil Falls 1%; US Services PMI Declines In June - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.02% to 42,216.40 while the NASDAQ gained 0.35% to 19,514.58. The S&P 500 also rose, gaining, 0.23% to 5,981.86. Consumer discretionary shares jumped by 1.6% on ...
Why Is Cidara Therapeutics Stock Trading Higher On Monday? - Cidara Therapeutics ( NASDAQ:CDTX )
CD388 showed 76.1% flu prevention efficacy at highest dose over 24 weeks. NAVIGATE trial met all primary and secondary endpoints with no safety issues. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. Cidara Therapeutics, Inc.
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Compass Pathways ( NASDAQ:CMPS ) , Cidara Therapeutics ( NASDAQ:CDTX )
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday. Following the market opening Monday, the Dow traded up 0.50% to 42,417.90 while the NASDAQ gained 0.61% to 19,566.92. The S&P 500 also rose, gaining, 0.62% to 6,004.66.
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza - Cidara Therapeutics ( NASDAQ:CDTX )
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo CD388 was well-tolerated with no safety signals ...
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
SAN DIEGO, May 08, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) ( the Company ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) therapeutics, today reported financial results for the first quarter ended March 31, ...
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics ( CDTX ) is a Great Choice
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
SAN DIEGO, April 24, 2025 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc. ( Nasdaq: CDTX ) , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ( DFC ) immunotherapies, today announced that it will report its first quarter 2025 financial results and ...
